November 7, 2024
Still leading the way
Looking over the results released by Insulet this afternoon several items stand out.
1. Insulet remains the leader in the insulin pump space.
2. While Tandem is making headway with the Mobi the threat to Insulet while real is not yet hurting overall growth.
3. Just one more piece of evidence that Medtronic is sinking deeper into the abyss.
4. The future looks equally bright and will get brighter now with the introduction of the Omnipod app which now controls the system.
5. The increase in guidance notably in overseas markets . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
